Previous 10 | Next 10 |
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2020 on Thursday, August 6, 2020, before the U.S. financial markets open. Management will provide an update o...
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
– Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS) Will Make Lumasiran Treatment Available for UK Primary Hyperoxaluria Type 1 (PH1) Patients Before Marketing Authorization -- – Lumasiran Indicated Within EAMS for the Treatment of Patients with P...
Blackstone ( BX -2.1% ) says its Blackstone Life Sciences V was oversubscribed and final close is at its hard cap of $4.6B of total capital commitments, making it the largest life sciences private fund raised till date. More news on: The Blackstone Group Inc., Alnylam Pharmaceuticals, ...
There's a number of upcoming catalysts in the liver disease treatment space, prompting Needham to update its takes on drugmakers targeting the diseases. More news on: Intercept Pharmaceuticals, Inc., Albireo Pharma, Inc., Mirum Pharmaceuticals, Inc., Healthcare stocks news, Notable Calls ...
− Long-Term Givosiran Dosing Showed Sustained Reduction in Annualized Rate of Composite Porphyria Attacks (AAR) With a Median AAR of Zero and Over 60 Percent of Patients Attack-Free in the Open-Label Extension Period − − Safety Profile Consistent With That Observed...
After many long years as a clinical-stage biotech, successful new drugs are beginning to pour out of Alnylam (NASDAQ: ALNY) . The FDA's currently reviewing the third new drug application from the biotech in as many years. Unfortunately for bargain shoppers, Alnylam's string of successes hasn...
Apropos for the pandemic era, ETFMG launches the ETFMG Treatments, Testing, and Advancements ETF, which seeks to invest in biotech companies that are engaged in testing and treatments of infectious diseases. More news on: Moderna, Inc., Alnylam Pharmaceuticals, Inc., Bio-Rad Laboratories, ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 7 th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer a range of presentations from Alnylam scientists and pr...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Securities 2020 Napa Biopharma Conference on Wednesday, June 24, 2020 at 10:30 am PT (1:30 pm ET) via webcast. A li...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...